免疫オンコロジーアッセイ市場の2030年までの予測：製品、適応症、技術、用途、地域別の世界分析

Stratistics MRCによると、世界の免疫オンコロジーアッセイ市場は2023年に50億4,000万米ドルを占め、予測期間中にCAGR 12.8％で成長し、2030年には117億1,000万米ドルに達すると予測されています。

免疫オンコロジーアッセイ市場とは、身体の免疫系を利用することでがんの研究および治療を支援するアッセイの開発および商業化に焦点を当てたヘルスケア産業内のセクターを指します。これらのアッセイは、新規の免疫腫瘍学的治療法の評価を可能にし、研究者が有望な候補を同定し、その有効性と安全性プロファイルを評価するのを支援することにより、医薬品開発において極めて重要な役割を果たしています。

ECISによると、欧州のがん患者数は2025年の294万人に対し、2040年には336万人に達すると予想されています。

免疫療法への関心の高まり

免疫療法は、身体の免疫システムを活用して腫瘍と効果的に闘う、がん治療の有望なアプローチとして浮上してきました。従来のがん治療はしばしば耐性に遭遇し、重篤な副作用を伴うことがあるため、免疫療法の魅力は、副作用が少なく、標的を絞った持続的な反応が期待できる点にあります。免疫腫瘍学的アッセイは、免疫療法剤の開発と評価に不可欠であり、研究者と臨床医がその有効性、安全性、作用機序を評価することを可能にします。

高い開発コスト

免疫腫瘍学的測定法の研究開発プロセスには、正確性、再現性、法規制への準拠を保証するための広範なバリデーション研究、測定法プロトコルの最適化、臨床バリデーション試験が含まれます。このような活動には、機器、試薬、人員、規制当局への申請など、多額の財政投資が必要です。経営資源が限られている中小企業にとって、高額な初期費用と長い開発期間は法外な負担となり、市場参入や大手既存企業との効果的な競合を阻む可能性があります。

技術の進歩

マルチプレックスアッセイ、次世代シーケンシング（NGS）、ハイスループットスクリーニングなどの技術革新は、研究者がより高い効率と精度で複数のパラメーターを同時に分析できるようにすることで、免疫腫瘍学の分野に革命をもたらしています。マルチプレックスアッセイでは、1つのサンプルで複数の分析項目を測定できるため、免疫系とがん細胞との複雑な相互作用に関する包括的な知見が得られます。NGS技術は、ゲノムおよびトランスクリプトーム・プロファイリングに前例のない機会を提供し、新規バイオマーカーや治療標的の同定を容易にします。

代替技術との競合

リキッドバイオプシーアッセイや画像診断法などの代替技術は、非侵襲性、リアルタイムモニタリング、包括的分子プロファイリングなどの明確な利点を提供します。これらの代替技術は、がんの進行、治療効果、患者の転帰に関する貴重な知見を提供する可能性があり、多くの場合、免疫腫瘍学的検査法の能力を補完する、あるいは凌駕します。その結果、研究者や臨床医は、特に免疫腫瘍学的アッセイがサンプルの入手可能性、アッセイの複雑さ、あるいはコストによって制限されるような環境では、これらの代替的アプローチを選択することができます。

COVID-19の影響：

当初、アウトブレイクによってサプライチェーン、検査室業務、臨床試験に混乱が生じ、アッセイ開発、バリデーション、商品化に遅れが生じました。また、必要でない医療行為や研究室活動の制限により、免疫腫瘍学研究の実施や臨床現場でのアッセイ技術の導入が妨げられました。さらに、ヘルスケア資源と資金がCOVID-19対策に振り向けられたため、免疫腫瘍学の研究開発から注目と投資が逸れました。しかし、パンデミックが進行するにつれ、免疫学や感染症研究の重要性が認識されるようになり、免疫オンコロジーアッセイへの関心や投資が喚起される可能性が出てきました。

予測期間中、消耗品セグメントが最大となる見込み

消耗品セグメントは、免疫オンコロジーアッセイの運用と拡張性をサポートする上で不可欠な役割を担っているため、予測期間中、市場で最大のシェアを占めました。がん罹患率の増加や免疫療法の普及に後押しされ、免疫オンコロジーアッセイに対する需要は増加の一途をたどっており、消耗品に対するニーズもそれに比例して高まっています。さらに、アッセイ開発における技術革新は、アッセイの感度、特異性、スループットを向上させるために設計された特殊な消耗品に依存することが多いです。このため、免疫オンコロジーアッセイ市場では消耗品に対する継続的な需要が生じています。

予測期間中、フローサイトメトリー分野のCAGRが最も高くなると予想される

フローサイトメトリー分野は、腫瘍微小環境における免疫細胞集団とその相互作用の解析における汎用性と精度の高さから、予測期間中に最も高いCAGRが見込まれます。この分野では、単一細胞レベルで複数のパラメータを同時に測定できるため、免疫細胞の表現型、活性化状態、機能的応答に関する貴重な知見が得られます。さらに、フローサイトメトリーによって免疫チェックポイントの発現やサイトカイン産生を評価できるため、免疫療法の有効性の評価や患者の層別化が容易になります。

最もシェアの高い地域

アジア太平洋地域が推定期間で最大のシェアを占めています。人口の急速な拡大、高齢化、ライフスタイルの変化に伴い、アジア太平洋諸国ではがんの罹患率と死亡率が急増しています。都市化、タバコ消費、公害、食習慣などの要因が、この地域におけるがん罹患率の上昇に寄与しています。その結果、ヘルスケアインフラの改善、診断サービスへのアクセス、がん検診プログラムの認知度が向上し、がん患者の早期発見・早期診断につながっています。

CAGRが最も高い地域：

欧州地域は、予測期間を通じて収益性の高い成長を遂げる見込みです。欧州医薬品庁（EMA）や欧州委員会などの欧州の規制機関によって確立された厳格な規制枠組みは、臨床研究や患者の治療に使用される免疫オンコロジーアッセイの安全性、有効性、品質を保証しています。欧州の規制環境は、透明性、エビデンスに基づく意思決定、倫理的配慮を重視しており、これらは利害関係者の間で免疫腫瘍学検査法に対する信頼と信用を築くことに貢献しています。その結果、規制遵守は、タイムリーな市場参入を促進し、技術革新を促し、欧州全域で精密医療と個別化がん治療のための免疫腫瘍学検査法の採用を促進することで、市場成長の要因としての役割を果たしています。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場プレイヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査資料
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 製品分析
• 技術分析
• 用途分析
• 新興市場
• COVID-19の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の免疫オンコロジーアッセイ市場：製品別

• ソフトウェア
• 消耗品
• 機器
• その他の製品

第6章 世界の免疫オンコロジーアッセイ市場：適応症別

• 膀胱がん
• メラノーマがん
• 肺がん
• 大腸がん
• 乳がん
• リンパ腫
• その他の適応症

第7章 世界の免疫オンコロジーアッセイ市場：技術別

• ポリメラーゼ連鎖反応（PCR）
• 免疫学的検査
• フローサイトメトリー
• 次世代シーケンシング（NGS）
• インサイチューハイブリダイゼーション
• その他のテクノロジー

第8章 世界の免疫オンコロジーアッセイ市場：用途別

• 臨床診断
• 研究用途
• その他の用途

第9章 世界の免疫オンコロジーアッセイ市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第10章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品発売
• 事業拡大
• その他の主要戦略

第11章 企業プロファイリング

• Agilent Technologies, Inc
• Bio-Rad Laboratories, Inc
• Charles River Laboratories, Inc
• F. Hoffmann-La Roche Ltd
• Guardant Health, Inc
• HTG Molecular Diagnostics, Inc
• llumina, Inc
• NanoString Technologies, Inc
• Novartis International AG
• Perkinelmer, Inc
• Qiagen Nv
• Sartorius AG
• Sysmex Corporation
• Thermo Fisher Scientific, Inc

List of Tables

• Table 1 Global Immuno Oncology Assay Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Immuno Oncology Assay Market Outlook, By Product (2021-2030) ($MN)
• Table 3 Global Immuno Oncology Assay Market Outlook, By Software (2021-2030) ($MN)
• Table 4 Global Immuno Oncology Assay Market Outlook, By Consumables (2021-2030) ($MN)
• Table 5 Global Immuno Oncology Assay Market Outlook, By Instruments (2021-2030) ($MN)
• Table 6 Global Immuno Oncology Assay Market Outlook, By Other Products (2021-2030) ($MN)
• Table 7 Global Immuno Oncology Assay Market Outlook, By Indication (2021-2030) ($MN)
• Table 8 Global Immuno Oncology Assay Market Outlook, By Bladder Cancer (2021-2030) ($MN)
• Table 9 Global Immuno Oncology Assay Market Outlook, By Melanoma Cancer (2021-2030) ($MN)
• Table 10 Global Immuno Oncology Assay Market Outlook, By Lung Cancer (2021-2030) ($MN)
• Table 11 Global Immuno Oncology Assay Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 12 Global Immuno Oncology Assay Market Outlook, By Breast Cancer (2021-2030) ($MN)
• Table 13 Global Immuno Oncology Assay Market Outlook, By Lymphoma (2021-2030) ($MN)
• Table 14 Global Immuno Oncology Assay Market Outlook, By Other Indications (2021-2030) ($MN)
• Table 15 Global Immuno Oncology Assay Market Outlook, By Technology (2021-2030) ($MN)
• Table 16 Global Immuno Oncology Assay Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
• Table 17 Global Immuno Oncology Assay Market Outlook, By Immunoassays (2021-2030) ($MN)
• Table 18 Global Immuno Oncology Assay Market Outlook, By Flow Cytometry (2021-2030) ($MN)
• Table 19 Global Immuno Oncology Assay Market Outlook, By Next-generation Sequencing (NGS) (2021-2030) ($MN)
• Table 20 Global Immuno Oncology Assay Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
• Table 21 Global Immuno Oncology Assay Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 22 Global Immuno Oncology Assay Market Outlook, By Application (2021-2030) ($MN)
• Table 23 Global Immuno Oncology Assay Market Outlook, By Clinical Diagnostics (2021-2030) ($MN)
• Table 24 Global Immuno Oncology Assay Market Outlook, By Research Applications (2021-2030) ($MN)
• Table 25 Global Immuno Oncology Assay Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 26 North America Immuno Oncology Assay Market Outlook, By Country (2021-2030) ($MN)
• Table 27 North America Immuno Oncology Assay Market Outlook, By Product (2021-2030) ($MN)
• Table 28 North America Immuno Oncology Assay Market Outlook, By Software (2021-2030) ($MN)
• Table 29 North America Immuno Oncology Assay Market Outlook, By Consumables (2021-2030) ($MN)
• Table 30 North America Immuno Oncology Assay Market Outlook, By Instruments (2021-2030) ($MN)
• Table 31 North America Immuno Oncology Assay Market Outlook, By Other Products (2021-2030) ($MN)
• Table 32 North America Immuno Oncology Assay Market Outlook, By Indication (2021-2030) ($MN)
• Table 33 North America Immuno Oncology Assay Market Outlook, By Bladder Cancer (2021-2030) ($MN)
• Table 34 North America Immuno Oncology Assay Market Outlook, By Melanoma Cancer (2021-2030) ($MN)
• Table 35 North America Immuno Oncology Assay Market Outlook, By Lung Cancer (2021-2030) ($MN)
• Table 36 North America Immuno Oncology Assay Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 37 North America Immuno Oncology Assay Market Outlook, By Breast Cancer (2021-2030) ($MN)
• Table 38 North America Immuno Oncology Assay Market Outlook, By Lymphoma (2021-2030) ($MN)
• Table 39 North America Immuno Oncology Assay Market Outlook, By Other Indications (2021-2030) ($MN)
• Table 40 North America Immuno Oncology Assay Market Outlook, By Technology (2021-2030) ($MN)
• Table 41 North America Immuno Oncology Assay Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
• Table 42 North America Immuno Oncology Assay Market Outlook, By Immunoassays (2021-2030) ($MN)
• Table 43 North America Immuno Oncology Assay Market Outlook, By Flow Cytometry (2021-2030) ($MN)
• Table 44 North America Immuno Oncology Assay Market Outlook, By Next-generation Sequencing (NGS) (2021-2030) ($MN)
• Table 45 North America Immuno Oncology Assay Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
• Table 46 North America Immuno Oncology Assay Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 47 North America Immuno Oncology Assay Market Outlook, By Application (2021-2030) ($MN)
• Table 48 North America Immuno Oncology Assay Market Outlook, By Clinical Diagnostics (2021-2030) ($MN)
• Table 49 North America Immuno Oncology Assay Market Outlook, By Research Applications (2021-2030) ($MN)
• Table 50 North America Immuno Oncology Assay Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 51 Europe Immuno Oncology Assay Market Outlook, By Country (2021-2030) ($MN)
• Table 52 Europe Immuno Oncology Assay Market Outlook, By Product (2021-2030) ($MN)
• Table 53 Europe Immuno Oncology Assay Market Outlook, By Software (2021-2030) ($MN)
• Table 54 Europe Immuno Oncology Assay Market Outlook, By Consumables (2021-2030) ($MN)
• Table 55 Europe Immuno Oncology Assay Market Outlook, By Instruments (2021-2030) ($MN)
• Table 56 Europe Immuno Oncology Assay Market Outlook, By Other Products (2021-2030) ($MN)
• Table 57 Europe Immuno Oncology Assay Market Outlook, By Indication (2021-2030) ($MN)
• Table 58 Europe Immuno Oncology Assay Market Outlook, By Bladder Cancer (2021-2030) ($MN)
• Table 59 Europe Immuno Oncology Assay Market Outlook, By Melanoma Cancer (2021-2030) ($MN)
• Table 60 Europe Immuno Oncology Assay Market Outlook, By Lung Cancer (2021-2030) ($MN)
• Table 61 Europe Immuno Oncology Assay Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 62 Europe Immuno Oncology Assay Market Outlook, By Breast Cancer (2021-2030) ($MN)
• Table 63 Europe Immuno Oncology Assay Market Outlook, By Lymphoma (2021-2030) ($MN)
• Table 64 Europe Immuno Oncology Assay Market Outlook, By Other Indications (2021-2030) ($MN)
• Table 65 Europe Immuno Oncology Assay Market Outlook, By Technology (2021-2030) ($MN)
• Table 66 Europe Immuno Oncology Assay Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
• Table 67 Europe Immuno Oncology Assay Market Outlook, By Immunoassays (2021-2030) ($MN)
• Table 68 Europe Immuno Oncology Assay Market Outlook, By Flow Cytometry (2021-2030) ($MN)
• Table 69 Europe Immuno Oncology Assay Market Outlook, By Next-generation Sequencing (NGS) (2021-2030) ($MN)
• Table 70 Europe Immuno Oncology Assay Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
• Table 71 Europe Immuno Oncology Assay Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 72 Europe Immuno Oncology Assay Market Outlook, By Application (2021-2030) ($MN)
• Table 73 Europe Immuno Oncology Assay Market Outlook, By Clinical Diagnostics (2021-2030) ($MN)
• Table 74 Europe Immuno Oncology Assay Market Outlook, By Research Applications (2021-2030) ($MN)
• Table 75 Europe Immuno Oncology Assay Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 76 Asia Pacific Immuno Oncology Assay Market Outlook, By Country (2021-2030) ($MN)
• Table 77 Asia Pacific Immuno Oncology Assay Market Outlook, By Product (2021-2030) ($MN)
• Table 78 Asia Pacific Immuno Oncology Assay Market Outlook, By Software (2021-2030) ($MN)
• Table 79 Asia Pacific Immuno Oncology Assay Market Outlook, By Consumables (2021-2030) ($MN)
• Table 80 Asia Pacific Immuno Oncology Assay Market Outlook, By Instruments (2021-2030) ($MN)
• Table 81 Asia Pacific Immuno Oncology Assay Market Outlook, By Other Products (2021-2030) ($MN)
• Table 82 Asia Pacific Immuno Oncology Assay Market Outlook, By Indication (2021-2030) ($MN)
• Table 83 Asia Pacific Immuno Oncology Assay Market Outlook, By Bladder Cancer (2021-2030) ($MN)
• Table 84 Asia Pacific Immuno Oncology Assay Market Outlook, By Melanoma Cancer (2021-2030) ($MN)
• Table 85 Asia Pacific Immuno Oncology Assay Market Outlook, By Lung Cancer (2021-2030) ($MN)
• Table 86 Asia Pacific Immuno Oncology Assay Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 87 Asia Pacific Immuno Oncology Assay Market Outlook, By Breast Cancer (2021-2030) ($MN)
• Table 88 Asia Pacific Immuno Oncology Assay Market Outlook, By Lymphoma (2021-2030) ($MN)
• Table 89 Asia Pacific Immuno Oncology Assay Market Outlook, By Other Indications (2021-2030) ($MN)
• Table 90 Asia Pacific Immuno Oncology Assay Market Outlook, By Technology (2021-2030) ($MN)
• Table 91 Asia Pacific Immuno Oncology Assay Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
• Table 92 Asia Pacific Immuno Oncology Assay Market Outlook, By Immunoassays (2021-2030) ($MN)
• Table 93 Asia Pacific Immuno Oncology Assay Market Outlook, By Flow Cytometry (2021-2030) ($MN)
• Table 94 Asia Pacific Immuno Oncology Assay Market Outlook, By Next-generation Sequencing (NGS) (2021-2030) ($MN)
• Table 95 Asia Pacific Immuno Oncology Assay Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
• Table 96 Asia Pacific Immuno Oncology Assay Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 97 Asia Pacific Immuno Oncology Assay Market Outlook, By Application (2021-2030) ($MN)
• Table 98 Asia Pacific Immuno Oncology Assay Market Outlook, By Clinical Diagnostics (2021-2030) ($MN)
• Table 99 Asia Pacific Immuno Oncology Assay Market Outlook, By Research Applications (2021-2030) ($MN)
• Table 100 Asia Pacific Immuno Oncology Assay Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 101 South America Immuno Oncology Assay Market Outlook, By Country (2021-2030) ($MN)
• Table 102 South America Immuno Oncology Assay Market Outlook, By Product (2021-2030) ($MN)
• Table 103 South America Immuno Oncology Assay Market Outlook, By Software (2021-2030) ($MN)
• Table 104 South America Immuno Oncology Assay Market Outlook, By Consumables (2021-2030) ($MN)
• Table 105 South America Immuno Oncology Assay Market Outlook, By Instruments (2021-2030) ($MN)
• Table 106 South America Immuno Oncology Assay Market Outlook, By Other Products (2021-2030) ($MN)
• Table 107 South America Immuno Oncology Assay Market Outlook, By Indication (2021-2030) ($MN)
• Table 108 South America Immuno Oncology Assay Market Outlook, By Bladder Cancer (2021-2030) ($MN)
• Table 109 South America Immuno Oncology Assay Market Outlook, By Melanoma Cancer (2021-2030) ($MN)
• Table 110 South America Immuno Oncology Assay Market Outlook, By Lung Cancer (2021-2030) ($MN)
• Table 111 South America Immuno Oncology Assay Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 112 South America Immuno Oncology Assay Market Outlook, By Breast Cancer (2021-2030) ($MN)
• Table 113 South America Immuno Oncology Assay Market Outlook, By Lymphoma (2021-2030) ($MN)
• Table 114 South America Immuno Oncology Assay Market Outlook, By Other Indications (2021-2030) ($MN)
• Table 115 South America Immuno Oncology Assay Market Outlook, By Technology (2021-2030) ($MN)
• Table 116 South America Immuno Oncology Assay Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
• Table 117 South America Immuno Oncology Assay Market Outlook, By Immunoassays (2021-2030) ($MN)
• Table 118 South America Immuno Oncology Assay Market Outlook, By Flow Cytometry (2021-2030) ($MN)
• Table 119 South America Immuno Oncology Assay Market Outlook, By Next-generation Sequencing (NGS) (2021-2030) ($MN)
• Table 120 South America Immuno Oncology Assay Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
• Table 121 South America Immuno Oncology Assay Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 122 South America Immuno Oncology Assay Market Outlook, By Application (2021-2030) ($MN)
• Table 123 South America Immuno Oncology Assay Market Outlook, By Clinical Diagnostics (2021-2030) ($MN)
• Table 124 South America Immuno Oncology Assay Market Outlook, By Research Applications (2021-2030) ($MN)
• Table 125 South America Immuno Oncology Assay Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 126 Middle East & Africa Immuno Oncology Assay Market Outlook, By Country (2021-2030) ($MN)
• Table 127 Middle East & Africa Immuno Oncology Assay Market Outlook, By Product (2021-2030) ($MN)
• Table 128 Middle East & Africa Immuno Oncology Assay Market Outlook, By Software (2021-2030) ($MN)
• Table 129 Middle East & Africa Immuno Oncology Assay Market Outlook, By Consumables (2021-2030) ($MN)
• Table 130 Middle East & Africa Immuno Oncology Assay Market Outlook, By Instruments (2021-2030) ($MN)
• Table 131 Middle East & Africa Immuno Oncology Assay Market Outlook, By Other Products (2021-2030) ($MN)
• Table 132 Middle East & Africa Immuno Oncology Assay Market Outlook, By Indication (2021-2030) ($MN)
• Table 133 Middle East & Africa Immuno Oncology Assay Market Outlook, By Bladder Cancer (2021-2030) ($MN)
• Table 134 Middle East & Africa Immuno Oncology Assay Market Outlook, By Melanoma Cancer (2021-2030) ($MN)
• Table 135 Middle East & Africa Immuno Oncology Assay Market Outlook, By Lung Cancer (2021-2030) ($MN)
• Table 136 Middle East & Africa Immuno Oncology Assay Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 137 Middle East & Africa Immuno Oncology Assay Market Outlook, By Breast Cancer (2021-2030) ($MN)
• Table 138 Middle East & Africa Immuno Oncology Assay Market Outlook, By Lymphoma (2021-2030) ($MN)
• Table 139 Middle East & Africa Immuno Oncology Assay Market Outlook, By Other Indications (2021-2030) ($MN)
• Table 140 Middle East & Africa Immuno Oncology Assay Market Outlook, By Technology (2021-2030) ($MN)
• Table 141 Middle East & Africa Immuno Oncology Assay Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
• Table 142 Middle East & Africa Immuno Oncology Assay Market Outlook, By Immunoassays (2021-2030) ($MN)
• Table 143 Middle East & Africa Immuno Oncology Assay Market Outlook, By Flow Cytometry (2021-2030) ($MN)
• Table 144 Middle East & Africa Immuno Oncology Assay Market Outlook, By Next-generation Sequencing (NGS) (2021-2030) ($MN)
• Table 145 Middle East & Africa Immuno Oncology Assay Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
• Table 146 Middle East & Africa Immuno Oncology Assay Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 147 Middle East & Africa Immuno Oncology Assay Market Outlook, By Application (2021-2030) ($MN)
• Table 148 Middle East & Africa Immuno Oncology Assay Market Outlook, By Clinical Diagnostics (2021-2030) ($MN)
• Table 149 Middle East & Africa Immuno Oncology Assay Market Outlook, By Research Applications (2021-2030) ($MN)
• Table 150 Middle East & Africa Immuno Oncology Assay Market Outlook, By Other Applications (2021-2030) ($MN)

According to Stratistics MRC, the Global Immuno Oncology Assay Market is accounted for $5.04 billion in 2023 and is expected to reach $11.71 billion by 2030 growing at a CAGR of 12.8% during the forecast period. The Immuno Oncology Assay Market refers to the sector within the healthcare industry focused on developing and commercializing assays that aid in the study and treatment of cancer by harnessing the body's immune system. These assays play a pivotal role in drug development by enabling the evaluation of novel immuno-oncology therapies, helping researchers identify promising candidates and assess their efficacy and safety profiles.

According to the ECIS, the European cancer burden is expected to reach 3.36 million new cases by 2040, compared to 2.94 million patients in 2025.

Market Dynamics:

Driver:

Growing interest in immunotherapy

Immunotherapy has emerged as a promising approach for cancer treatment, leveraging the body's immune system to combat tumors effectively. As traditional cancer treatments often encounter resistance and can have severe side effects, the appeal of immunotherapy lies in its potential for targeted and durable responses with fewer adverse effects. Immuno-oncology assays are integral to the development and evaluation of immunotherapeutic agents, allowing researchers and clinicians to assess their efficacy, safety, and mechanism of action.

Restraint:

High development costs

The research and development (R&D) process for immuno-oncology assays involves extensive validation studies, optimization of assay protocols, and clinical validation trials to ensure accuracy, reproducibility, and regulatory compliance. These activities require substantial financial investment, including expenditures on equipment, reagents, personnel, and regulatory submissions. For smaller companies with limited resources, the high upfront costs and long development timelines can be prohibitive, preventing them from entering the market or competing effectively with larger established players.

Opportunity:

Technological advancements

Innovations such as multiplex assays, next-generation sequencing (NGS), and high-throughput screening are revolutionizing the field of immuno-oncology by enabling researchers to analyze multiple parameters simultaneously with greater efficiency and precision. Multiplex assays allow the measurement of multiple analytes in a single sample, providing comprehensive insights into the complex interactions between the immune system and cancer cells. NGS technologies offer unprecedented opportunities for genomic and transcriptomic profiling, facilitating the identification of novel biomarkers and therapeutic targets.

Threat:

Competition from alternative technologies

Alternative technologies such as liquid biopsy assays or imaging modalities offer distinct advantages, such as non-invasiveness, real-time monitoring, and comprehensive molecular profiling. These alternatives may provide valuable insights into cancer progression, treatment response, and patient outcomes, often in ways that complement or surpass the capabilities of immuno-oncology assays. As a result, researchers and clinicians may opt for these alternative approaches, particularly in settings where immuno-oncology assays may be limited by sample availability, assay complexity, or cost.

Covid-19 Impact:

Initially, the outbreak led to disruptions in supply chains, laboratory operations, and clinical trials, causing delays in assay development, validation, and commercialization. Restrictions on non-essential medical procedures and laboratory activities also hindered the conduct of immuno-oncology research and the adoption of assay technologies in clinical settings. Furthermore, the redirection of healthcare resources and funding towards COVID-19 response efforts diverted attention and investment away from immuno-oncology research and development. However, as the pandemic progressed, there emerged a heightened recognition of the importance of immunology and infectious disease research, potentially stimulating interest and investment in immuno-oncology assays.

The consumables segment is expected to be the largest during the forecast period

Consumables segment dominated the largest share of the market during the forecast period due to its indispensable role in supporting the operation and scalability of immuno-oncology assays. As the demand for immuno-oncology assays continues to rise, fueled by increasing cancer prevalence and the growing adoption of immunotherapy, the need for consumables also escalates proportionally. Moreover, innovations in assay development often rely on specialized consumables designed to improve assay sensitivity, specificity, and throughput. This creates a continuous demand for consumables within the immuno-oncology assay market.

The flow cytometry segment is expected to have the highest CAGR during the forecast period

Flow Cytometry segment is expected to have the highest CAGR during the projection period due to its versatility and precision in analyzing immune cell populations and their interactions within the tumor microenvironment. This segment allows for the simultaneous measurement of multiple parameters at the single-cell level, providing valuable insights into immune cell phenotypes, activation states, and functional responses. Additionally, flow cytometry enables the assessment of immune checkpoint expression and cytokine production, facilitating the evaluation of immunotherapy efficacy and patient stratification.

Region with largest share:

Asia Pacific region commanded the largest share over the extrapolated period. With a rapidly expanding population, aging demographics, and changing lifestyles, countries across Asia Pacific are experiencing a surge in cancer incidence and mortality rates. Factors such as urbanization, tobacco consumption, pollution, and dietary habits contribute to the rising burden of cancer in the region. As a result, improvements in healthcare infrastructure, access to diagnostic services, and awareness of cancer screening programs are leading to earlier detection and diagnosis of cancer cases in the region thereby enhancing the market growth.

Region with highest CAGR:

Europe region is poised to witness profitable growth throughout the estimation period. The stringent regulatory framework established by European regulatory bodies, such as the European Medicines Agency (EMA) and the European Commission, ensures the safety, efficacy, and quality of immuno-oncology assays used in clinical research and patient care. The European regulatory environment emphasizes transparency, evidence-based decision-making, and ethical considerations, which contribute to building trust and confidence in immuno-oncology assays among stakeholders. As a result, regulatory compliance serves as a catalyst for market growth by facilitating timely market entry, encouraging innovation, and promoting the adoption of immuno-oncology assays for precision medicine and personalized cancer care throughout the European region.

Key players in the market

Some of the key players in Immuno Oncology Assay market include Agilent Technologies, Inc, Bio-Rad Laboratories, Inc, Charles River Laboratories, Inc, F. Hoffmann-La Roche Ltd, Guardant Health, Inc, HTG Molecular Diagnostics, Inc, llumina, Inc, NanoString Technologies, Inc, Novartis International AG, Perkinelmer, Inc, Qiagen Nv, Sartorius AG, Sysmex Corporation and Thermo Fisher Scientific, Inc.

Key Developments:

In January 2024, Thermo Fisher Scientific introduced Gibco(TM) Cell Therapy Systems (CTS(TM)) Cellmation(TM) Software, a new automation solution. It integrates workflows across Thermo Fisher Scientific cell therapy instruments and ensures cGMP compliance for innovators in breakthrough cell therapies.

In March 2023, Mimetas, a company that models human diseases, formed a strategic alliance with Astellas Pharma Inc., a multinational pharmaceutical corporation. The partnership entails using MIMETAS' exhaustive tumor models to assist the next generation of immuno-oncological therapies.

In February 2023, Agilent Technologies, Inc. revealed that their xCELLigence RTCA HT (real-time cell analysis high-throughput) platform is compatible with the BioTek BioSpa 8 Automated Incubator. This combination, developed in response to market demands, enables a higher level of workflow automation and provides novel functionality for developing label-free high-throughput potency assays for the immuno-oncology market and high-throughput viral cytopathic effects (CPE) assays for the vaccine market.

Products Covered:

• Software
• Consumables
• Instruments
• Other Products

Indications Covered:

• Bladder Cancer
• Melanoma Cancer
• Lung Cancer
• Colorectal Cancer
• Breast Cancer
• Lymphoma
• Other Indications

Technologies Covered:

• Polymerase Chain Reaction (PCR)
• Immunoassays
• Flow Cytometry
• Next-generation Sequencing (NGS)
• In Situ Hybridization
• Other Technologies

Applications Covered:

• Clinical Diagnostics
• Research Applications
• Other Applications

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Technology Analysis
• 3.8 Application Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Immuno Oncology Assay Market, By Product

• 5.1 Introduction
• 5.2 Software
• 5.3 Consumables
• 5.4 Instruments
• 5.5 Other Products

6 Global Immuno Oncology Assay Market, By Indication

• 6.1 Introduction
• 6.2 Bladder Cancer
• 6.3 Melanoma Cancer
• 6.4 Lung Cancer
• 6.5 Colorectal Cancer
• 6.6 Breast Cancer
• 6.7 Lymphoma
• 6.8 Other Indications

7 Global Immuno Oncology Assay Market, By Technology

• 7.1 Introduction
• 7.2 Polymerase Chain Reaction (PCR)
• 7.3 Immunoassays
• 7.4 Flow Cytometry
• 7.5 Next-generation Sequencing (NGS)
• 7.6 In Situ Hybridization
• 7.7 Other Technologies

8 Global Immuno Oncology Assay Market, By Application

• 8.1 Introduction
• 8.2 Clinical Diagnostics
• 8.3 Research Applications
• 8.4 Other Applications

9 Global Immuno Oncology Assay Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Agilent Technologies, Inc
• 11.2 Bio-Rad Laboratories, Inc
• 11.3 Charles River Laboratories, Inc
• 11.4 F. Hoffmann-La Roche Ltd
• 11.5 Guardant Health, Inc
• 11.6 HTG Molecular Diagnostics, Inc
• 11.7 llumina, Inc
• 11.8 NanoString Technologies, Inc
• 11.9 Novartis International AG
• 11.10 Perkinelmer, Inc
• 11.11 Qiagen Nv
• 11.12 Sartorius AG
• 11.13 Sysmex Corporation
• 11.14 Thermo Fisher Scientific, Inc